HCV Research

Track Funding


HCV Funded Studies:

HCV Research

HIV Research

Hepatitis B & Viral Hepatitis" Studies

Liver Disease Research

Unknown Category Research


Charts & Data

Treatments

Clinical Trials

Cirrhosis, HCC & Transplant Research

Mental Health

Harm Reduction

Snapshot NIH-TransPlan for HCV Funding


 

 

PRESS RELEASE:
Millions of  Dollars Redirected HepCop has publicly denounced the National Institutes of Health (NIH) for spending millions of dollars budgeted for Hepatitis C (HCV) on other research agendas.


HCV Grants:
HCV, HIV & HIV/HCV Harm Reduction Research Projects

 
USA Population Positive for HCV
 

Society in Jeopardy

The largest public health patient notification in the history of the USA occurred this year, FY 2008. Public health sent in excess of 70,000, letters warning of possible HCV exposure from unsafe medical practices involving several clinics.[11]  Following a joint investigation with the Nevada State Bureau of Licensure and Certification (BLC) and with consultation from the CDC, identified the re-use of syringes (not needles) and the use of single dose vials of anesthesia medication on multiple patients, as the potential sources of contamination.

The Southern Nevada Health District reported that 200 people are testing positive daily in public health departments. [12]  Ironically, the head of the CDC, Julia Louise Gerberding says; "The outbreak of HCV may represent the tip of an iceberg” of safety problems at clinics around the country". [13]

After similar outbreaks in New York, the FDA has rejected that state's request to ban multidose vials[14], saying the vials are critical in hospital use. [15]  The CDC says, "Use all vials labeled as "single-use" for one patient and entered one time only". "Assign medications packaged as multidose to a single patient whenever possible." [16]

Multidose vials fail in comparison to the impertinence for standard procedures. The World Health Organization states, "The only means of protection from the Hepatitis C virus are the implementation universal precautions and safe injection practices." Nation-wide, from 2004-2008, tens of thousand medical exposures to HCV have occurred with an undetermined number of positive infections because of policy differences. Medical exposures surpass any other risk factor for HCV infections.[17]


HCV Harm Reduction Grants

Grants Project Number Researcher Cost Project Title
NCRR 5M01RR000827-33 HAHN, JUDITH $424,754  EFFECTS OF METHAMPHETAMINE & HCV
NIAAA 1R21AA017252-01A1 MUIR, ANDREW $224,250  Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Use/Abuse
NIDA 5R01DA023570-02 GARCIA-TSAO, GUADALUPE $244,622  Stabilize Addiction/Affect, Begin Inmates' Interferon for HCV of Liver (STAABIHL)

$420,608

5K23DA018623-05 FLOTTE, TERENCE $175,986  Pre-Chemotherapeutic Care of HCV Infected Drug Users
NIAAA 5R01AA016231-03 RANEY, KEVIN $389,191  Lifetime Drinking Patterns & HCV Treatment Outcomes
NIDA 5R01DA016078-07 STERLING, RICHARD $712,636  The Progression of Hepatitis C Among IDUs
$2,843,420 5R01DA016159-05 EINAV, SHIRIT $650,470  Acute HCV Infection in Injection Drug Users
5R01DA016017-06 OTT, MELANIE $466,965  Acute Hepatitis C Infection in Young Injectors
1K23DA022454-01A1 LIU, HONGJIE $178,897  Directly Observed Hepatitis C Treatment in Methadone Clinics
1R01DA021550-01A2 EINAV, SHIRIT $834,452  HCV Transmission among Young IDUs in NYC
Total Spending $4,302,223  


 NIH Spends Most of HCV Harm Reduction Funding for HIV/ Coinfection, Drug & Alcohol Abuse

Grants Project Number Researcher Cost Project Title
FIC 5R01TW006972-04 RANEY, KEVIN $51,202  Risk Factors for HIV-1 infection Among Young Thai Men
NIAAA 2R37AA014372-06A1 SHOHDY, NADIM $368,063  HCV, Alcohol and Host Defense
$2,034,407 3R13DA026294-01S1 HELLER, THEO $15,000  Sino-US Symposium in Drug Abuse, HIV and HCV Comorbidity
5R01AA015201-03 NORTH, CAROL $682,443  Psychoeducation for HCV and Alcohol Behaviors
5R01AA008169-19 TARAKHOVSKY, ALEXANDER $323,323  HCV in Alcoholics
5R01AA012863-09 TAYLOR, LYNN $501,982  Mechanisms of Liver Injury by Hepatitis C and Alcohol
1F31AA017853-01 WHITE, DONNA $40,972  Effect of alcohol and opioids on DC function in HCV and HIV infection
1R01AA018001-01 MCCANCE-KATZ, ELINORE $437,882  Interaction of Alcohol and HAART in HIV/AIDS and HIV/AIDS and HCV Coinfection
3R01AA015201-02S1 NORTH, CAROL $32,805  Psychoeducation for HCV and Alcohol Behaviors
NIDA 5K01DA017179-05 RAY, RATNA $169,492  HCV Treatment Cost-Effectiveness in 3 IDU Populations
$4,478,757 5R01DA020781-03 MASSON, CARMEN $331,144  Hepatitis Care Coordination in Methadone Treatment
1R21DA023893-01A1 LO RE, VINCENT $215,840  Mediation Effect of Network Function on Transition to Injection Drug Use
5R01DA010164-12 BOURGOIS, PHILIPPE $360,811  The Logics for HIV Risk Among Homeless Heroin Injectors
5R01DA022177-02 HOWARD, ANDREA $402,864  Opioids, HIV/HCV and Host Cell Innate Immunity
5R01DA020841-03 PANDEY, JANARDAN $354,372  Hepatitis Care Coordination in Methadone Treatment
5R01DA022030-03 BROWN, LAWRENCE $179,626  Electronic Information System to Enhance Practice at an Opioid Treatment Program
5K01DA023365-02 HARTGE, PATRICIA $165,521  Dynamic Modeling of the HCV Epidemic in IDU
5R01DA019383-04 GALE, MICHAEL $599,233  Staying Safe: Long-Term Injection Drug Users Who Have Avoided HIV & Hepatitis C
1K23DA020383-01A1 SPRATT, HEIDI $179,212  Buprenorphine as a Bridge to HCV Treatment for HIV/HCV Coinfected Opioid Users
5R01DA019829-04 SCOTT, JOHN $706,524  Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in Tijuana
5R21DA023399-02 RAISON, CHARLES $150,780  Reducing HIV Risk Among Methamphetamine IDUs Through Peer Education
3R01DA019829-03S1 SCOTT, JOHN $54,773  Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in Tijuana
2R01DA016065-06A1 SHERMAN, KENNETH $402,468  HCV Disease Management in HIV- HCV Coinfected IDUs
1R13DA026294-01 HELLER, THEO $25,000  Sino-US Symposium in Drug Abuse, HIV and HCV Comorbidity
3R01DA022177-01A1S2 HOWARD, ANDREA $7,020  Opioids, HIV/HCV and Host Cell Innate Immunity
5K23DA022143-03 BRUCE, ROBERT $174,077  Substance Abuse, HIV and HCV Treatments to Improve Health Outcomes in Drug Users
Total Spending $6,932,429  

Risk for Coinfection
No evidence of a hepatitis C epidemic in HIV negative gay men
The study found that the likelihood of being newly diagnosed with hepatitis C was not significantly greater in gay men than it was in heterosexual men, and hepatitis C infection was much more strongly associated with having HIV than it was with sexual orientation.  

Washington State HIV/AIDS Surveillance Report - 05/31/2007
2007 YTD
  •   21 % had No known risk factor identified
  •   5% identified as IDU

Latest Research
From the Scientists
Sexual Transmission of HCV Is Uncommon Among Heterosexual Injection Drug Users "Our results are consistent with prior research indicating that sexual contact plays little role in HCV transmission.
 

Senate Report 110-410 - DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION, AND RELATED AGENCIES APPROPRIATION BILL, 2009

Full Display
Related Information
PDF
Printer Friendly Display
Bill Summary and Status
Full Text of Bill

*The Committee is aware that over 30 percent of HIV-infected persons in the United States are chronically infected with the hepatitis C virus [HCV]. The Committee recognizes the materials and conferences HRSA has engaged in on this subject and supports the effort to adjust the ADAP formulary to reduce the morbidity and mortality of this population. In addition, the Committee encourages HRSA to highlight best practices regarding treatment of co-infected patients.

*The Ryan White HIV/AIDS Treatment Modernization Act requires that not less than 75 percent of appropriated funds under parts A through C must be spent on core medical services. (note: to qualify, you must have an HIV risk factors)
 

 

Source: National Institutes of Health Research Portfolio Online Reporting Tool (RePORT) Reports,
Data and Analyses of NIH Research Activities
Retrieved on March 18, 2009
http://report.nih.gov/rcdc/categories/ProjectSearch.aspx?FY=2008&DCat=Hepatitis+-+C

Permission is granted to use all information from this website in pursuit of ending NIH's "Trans-Plan" discriminatory practices against HCV research funding allocations. Please Credit: HCVets.com Educational Website & Support Forums for Military Related HCV Exposures.

Contact HepCop   
Email:
Staff